Shire plays heavy metal

Sales of Genzyme's Renagel sevelamer phosphate binder, which is marketed to lower plasma phosphorus levels in patients on dialysis, have grown dramatically since the company began presenting data showing that the alternative - inexpensive calcium tablets like Tums - can cause cardiovascular calcification.

Read the full 436 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE